The most prominent function of progesterone in endometrium is the shift from a proliferative to a secretory state to prepare the endometrium for establishing receptivity for the embryo. During this short period, the implantation "window" [I] , the endometrium is permissive for blastocyst implantation; after this time, the eridometrium becomes hostile for the blastocyst [2] . Identification of markers specific to this period would be useful to facilitate a diagnosis of infertility attributable to lack of uterine receptivity. During the period of receptivity, the trophoblast of the blastocyst has to attach to the apical membrane of the endometrial epithelium-an event that has been seen as a cell biology paradox [4, 5] . Numerous changes under the control of progesterone and estrogen acting together take place in the apical membrane, allowing it to acquire adhesive properties (for a review see Murphy and Shaw [6] ). Among these changes are large apical protrusions referred to as "pinopods," known to be progesterone-dependent [7] , which have been described as markers of the uterine receptivity [8] . We recently demonstrated that progesterone decreased the concentration of cystic fibrosis transmembrane conductance regulator (CFTR) mRNA in cultured epithelial cells of guinea pig endometrium [9] . Because CFTR is located in the apical membrane of epithelium [10] , this effect of progesterone might represent an early event to prepare apical membrane for embryo implantation and could be a useful specific marker for defining the state of receptivity in endometrium, especially in human endometrium.
To detect low amounts of CFTR mRNA in human endometrial samples, we developed a competitive reverse transcription-polymerase chain reaction (RT-PCR) Measuring CFTR mRNA by quantitative RT-PCR has been already described, with use of a constitutively expressed mRNA-for /3-actin [11] or aldolase [12] -as an endogenous external standard. The competitive RT-PCR described here measures CFTR mRNA by using an exogenous internal standard cRNA that exhibits the same sequence as the target sequence except for a 20-nucleotide insertion in the standard. When the cRNA and target mRNA are co-reverse-transcribed and amplified with the same primer set, the cRNA competes with the target RNA. Thus, in this method, the ratios of the amplified products precisely reflect the initial concentration of target RNA in relation to that of the added competitor, independently of the total amounts of amplified fragments generated by the reaction [13] .
Using this competitive RT-PCR, we have measured the CFTR mRNA present in human endometrial samples. To amplify a region of the CFTR cDNA represented with the exons of interest (10-13), we chose one set of external primers from a specific region in exon 10 for the forward primer (cf569 N) and another set in exon 13 for the reverse primer (cf567l). 17 promoter sequence (T7 promoter) was added at the 5' end of the forward primer. Another set of internal contiguous primers were chosen in exon 11 with complementary lwhite rectangle) 20-bp fragments at their 5' ends (A and B), unrelated to the target sequence. The location of primers in DNA are indicated in the shaded boxes. cf569N and cf5671 as in ref.
11.
Materialsand Methods

PATIENTS AND SAMPLES
Endometrium biopsies were performed on women as part of their evaluation for infertility in the Service de Gyn#{233}cologie et Obstetrique (CHU, Besancon). All patients gave informed consent. All patients were having normal ovarian cycles. The cycle stage of the endometrium was assessed by ultrasound, last menstrual period, timing of ovulation, and histological observations, according to the criteria of Noyes et al. [14] . Biopsies "in phase" with these physiological, physical, and histological criteria were retained as "normal" for the present study. Hyperplasia suggested by ultrasound was confirmed by the histological criteria [15] . Histological diagnoses were as follows: normal proliferative (n = 6), including early and middle (n = 2) and late (n = 4) proliferative; or secretory (n 4), including middle (n = 1) and late (n = 3) secretory; or simple hyperplasia (n = 2). Five biopsies from patients with endometriosis were late proliferative (n = 3) or late secretory (n = 2).
Biopsies were frozen and maintained in liquid nitrogen before use for RNA extraction.
Aliquots of each biopsy were fixed for microscopic viewing before being sent for pathological diagnosis and staging of the endometrium.
CONSTRUCTION OF INTERNAL STANDARD (COMPETITOR)
Two primers were chosen to amplify a 3 l3-bp fragment of the CFT'R cDNA. The forward primer, cf569N, 5 '-GTTTTCCT-GGA'TTATGCCTGGCAC-3', is located in exon 10, coding a part of the NBFI region; the reverse primer,
is located in exon 13, coding a part of the R domain region [12] . Using modified cf569N and cf5671 as external primers, we constructed as competitor cRNA of the same length and sequence as CFTR mRNA except for a 20-nucleotide insertion in the middle. Construction of this competitor was accomplished in two steps, following the technique of Diviacco et al. [13] , modified as described by Vanden Heuvel et al. [16] to obtain a cRNA.
In the first step, heteroduplex DNA fragments were synthesized with the same length and sequence as target cDNA, with two exceptions: a 20-bp insertion in the middle and the recognition sequence of the T7 RNA polymerase at one end. For this we used four specific primers (Fig. 1) , two external and two internal. The two external primers were: #{149} a forward outside primer corresponding to cf569N primer containing 19 5'-appended (underlined) bp for the T7 promoter(T7-cf569N):
5 '-TAATACGACTCACTATAGGGT-TTTCCTGGATTATGCCTGGCAC-3' #{149} a reverse outside primer corresponding to cf5671 primer
The two internal primers were:
#{149} an inside forward primer (A) corresponding to a sequence of 23 bpin exon 11 (1751-1774N)inCFTRcDNA [16] Using these four primers, we carried out two separate amplifications with two sets of primers (T7-cf569N plus B, and cf5671 plus A), giving rise to two hemiamplification fragments of 194 and 179 bp that contained a single overlapping region of 20 bp. These products were separated by electrophoresis on 8% polyacrylamide gel and visualized by staining with ethidium bromide (Fig. 2, lanes 1 and 2) . The two bands were eluted from the gel with 50 iL of distilled water. After one night at 4 #{176}C, 50 L of eluate was added to 50 .tL of PCR amplification mixture, containing 10 L of lOX PCR buffer (100 mmollL Tris-HCI, mm at 94#{176}C, then cycled with the PCR cycle profile of (for the first 5 cycles) 1.50 mm at 94#{176}C, 2 mm at 65 #{176}C, and 3 mm at 72 #{176}C. To amplify the heteroduplex, we added 0.7 .tmolIL each of cfS69N and cf5671 primers and performed the amplification for 30 cycles as follows: 1,30 mm at 94#{176}C, 2 mm at 62 #{176}C, and 3 mm at 72 #{176}C; this gave rise to a 352-bp DNA fragment (Fig.  2, lane 3) corresponding to the heteroduplex containing the 20-bp insertion.
To verify the insertion, we sequenced the heteroduplex by the dideoxy-chain-termination method [18] , using the Amplitaq kit (Perkin-Elmer, Saint Quentin-enYvelines, France). The sequence analysis showed that the 20 inserted nucleotides were in the middle of the 173 5-1764 [11] CFTR cDNA region in exon 11 (Fig. 3) .
In the second step, competitor RNA derived from the heteroduplex containing the T7 promoter sequence was prepared by in vitro transcription with the Riboprobe gemini II core system (Promega, Coger, Paris, France) as described by
Vanden Heuvel et al. [16] . 260 nm. The RT-PCR products were visualized as a 33 3-bp fragment (Fig. 2, lane 4) and a 31 3-bp (target) fragment in 8% polyacrylamide gel electrophoresis (Fig. 2, lane 5) .
COMPETITIVE RT-PCR FOR EVALUATION OF CFTR MRNA
RNA was extracted from biopsies with TRIZOL Reagent (Gibco BRL, Life Technologies, Gaithersburg, MD) followed by ethanol precipitation.
For co-reverse transcription of 5 g of total RNA and various amounts of RNA competitor, we used 5 mmoVL cf5671 primer (final volume: 50 giL) in the RT-PGR kit (Stratagene).
The PCR assay was carried out in a Quatro AT CG 20 nt 
Results and Discussion
COMPETITIVE
RT-PCR FOR EVALUATION OF CFTR MRNA
To determine the mRNA content of CFTR in human endometrial samples, we developed a competitive RT-PCR in which target RNA and competitor were co-reverse-transcribed and amplified in the same tube, yielding amplification products of 313 and 333 bp, respectively.
Because it was important to verify that the target and competitor were amplified with the same efficiency, we compared the amplification kinetics of approximately equal amounts of CFT'R and competitor.
As shown in Fig. 4 , the competitor fragment and the CFTR sequence were amplified with the same efficiency for all values of n (number of amplification cycles). Being independent of cycle number, therefore, the competitive RT-PCR did not require the exponential phase of amplification [13] . Consequently, we performed all experiments for 30 cycles. To quantify the amplified products, we carried out the determinations with at least three increasing amounts of com- Total RNA was extracted from a human endometrial sample. Nearly equal amounts of CFTRand competitor RNA were co-reverse-transcribed and amplified for various numbers of cycles. The RT-PCRproducts were then electrophoresed and the bands were stained with ethidium bromide. Band staining was measured by densitometric scanning, and values were expressed as log band areas. We co-reverse-transcribed and amplified with various concentrations of compet. itor 5 g of total RNA from the endometrial samples. (Top) The RT-PCRproducts of competitor (333 bp) and CFTR(313 bp) were separated by electrophoresis on 8% polyacrylamlde gel and visualized by staining with ethidium bromide. (Bottom) Bands of the amplified products were quantified by densitometric scanning, and the log of the number of competitor molecules (amol) added to the sample before RT-PCRwas plotted against the log of the CETR/competitor band area ratios obtained after RT-PCR.
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Mularoni et al.: CFTR mRNA quantified in human endometrium petitor and 5 xg of total RNA; from this, we could estimate the equivalency point between competitor and CFTR bands. Fig. 5 shows the RT-PGR products obtained from one sample containing a high amount of CFTR mRNA (A) and from another with a low amount (B). The intensity of the bands from competitor products (333 bp) decreased as the concentration of added competitor decreased, and the product of CFTR mRNA (313 bp) increased as the competitor product decreased (Fig. 5,   top panels, A and B) . Areas of the competitor and CFTR bands N were quantified by densitometric scanning of the stained gel. Because the amplification efficiencies of target and competitor were identical, the ratio between the two reverse-transcribed and amplified fragments depended exclusively on the initial ratio between CFTR and competitor RNA. Thus, we could graph the log of the ratios between CFTR and competitor products as a function of the initial amount of competitor added to the RT-PGR reaction. As shown in Fig. 5 , this function is linear, and the equivalent CFTR mRNA amount present in the 5-.tg RNA samples (log ratio = 0) was obtained at 73.4 amol (Fig. 5A) and 5.5 amol (Fig. 5B) . Fig. 5 however, these variations were not significant. Although only one sample was obtained during cycle days 18-21, this sample contained the lowest amount of CFTR mRNA (5.5 amolJ5 p.g total RNA). Samples from patients with endometriosis showed no significant variation in comparison with the other samples.
The highest late-secretory CFTR mRNA values occurred in samples from patients with hyperplasia (confirmed by the histological criteria). In spite of the small number of samples, this preliminary analysis demonstrated variations in CFTR mRNA concentrations during the menstrual cycle, especially for the sample from the 20th day of the cycle, where the CFTR mRNA concentration was very low. The 20th day corresponds to the period of receptivity of endometrium for embryo implantation [2] ; during this period, the concentration of progesterone in serum is the highest. This result is in good agreement with previous results [9] . Thus, the quantity of CFT'R mRNA expressed could be a good marker representative of the state of endometrium receptivity in biopsies taken between the 18th and 21st days of the menstrual cycle. Another notable result was the increase in CFTR mRNA in the two hyperplastic samples studied.
We conclude that the competitive RT-PCR is suitable for studying variations in the CFTR mRNA concentration in endometrium to study the regulation of CFTR expression. This study will be continued, to confirm the preliminary results.
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